Some 12,000 troops to take part in post-Soviet security bloc’s drillsMilitary & Defense September 26, 15:48
Germany remains one of Russia’s key partners in Europe — KremlinRussian Politics & Diplomacy September 26, 15:33
Russian Defense Ministry calls on UN to increase humanitarian aid to SyriaWorld September 26, 14:59
Kremlin says open skies treaty controversies must be settled within pact's frameworkRussian Politics & Diplomacy September 26, 14:31
Embassy of Spain evacuated in Moscow due to bomb scareWorld September 26, 14:21
Putin discusses Kurdish referendum with Erdogan, RouhaniRussian Politics & Diplomacy September 26, 14:03
Russia may create 'drone swarms' capable of making decisions in 5 yearsMilitary & Defense September 26, 14:01
Kremlin urges Facebook to honor Russian lawsBusiness & Economy September 26, 13:53
Russian army to get bulk of Terminator armored vehicles in 2018Military & Defense September 26, 13:33
NOVOSIBIRSK, November 14 (Itar-Tass) - Scientists at Russia's SibEnzyme enterprise in the Siberian city of Novosibirsk have developed a brand new method to diagnose oncological diseases at very early stages, the company’s chief executive, Yevgeny Dubinin, told Itar-Tass at the international forum for technological development Technoprom.
The new method allows to detect cancer cells even if the sample under scrutiny (blood, phlegm, urine or smear) contains only few DNA molecules with abnormally methylated (abnormally working, ‘silent’ genes), according to Dubinin.
The company’s enzyme, whose patented technology detects methylated genes, is used as a tumor marker. Analysis is simple and reliable - carried out on standard equipment, in one vial and in three stages, it takes only about four hours.
“There is almost no early cancer diagnostic in Russia, while treating the disease when it is detected at the third and fourth stages yields little effect,” Dubinin said.
The new method will be indispensable for oncological centres, diagnostic laboratories, and other medical institutions, the director added. The estimated market volume is about 5.5 million examinations and 1.8 million for rare types of cancer.